MedTrace Logo

Flupenthixol Decanoate in Methamphetamine Smoking - 1

NCT00000241 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2017-01-12

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of flupenthixol decanoate for treatment of methamphetamine dependence. Also, study will compare flupenthixol with desipramine in blocking methamphetamine self-administration.

Conditions

  • Substance-Related Disorders

Interventions

DRUG

Flupenthixol

Sponsors & Collaborators

  • Friends Research Institute, Inc.

    collaborator OTHER

  • National Institute on Drug Abuse (NIDA)

    lead NIH

Principal Investigators

  • Frank Gawin, M.D. · Friends Research Institute, Inc.

Study Design

Purpose
TREATMENT

Eligibility

Min Age
22 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1994-02-28
Completion
1996-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000241 on ClinicalTrials.gov